{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"}],"units":"Participants"}],"description":"Number of participants with an objective response of Partial Response (PR) or better according to European Society for Blood and Marrow Transplantation (EBMT) criteria within 180 days post Expanded Natural Killer Cell Infusion. The minimum criteria to meet the EBMT definition of PR or better included: \\>= 50% reduction in size of soft tissue plasmacytomas (if assessed); AND \\>= 50% reduction in plasma cells in bone marrow biopsy (if biopsy was performed and if \\>= 30% plasma cells at baseline); AND \\>=50% reduction in serum M protein and reduction in urine M protein \\>= 90% or to 200 mg/24hr OR \\>= 50% decrease in the difference between involved and uninvolved serum free light chain levels (if serum M protein \\< 1 g/dL, urine \\< 200 mg/24 hrs, and an involved serum free light chain level \\>= 10 mg/dL at baseline).","groups":[{"description":"Day(s) -9,-6,-2 3 doses of Bortezomib at 1.0 mg/m2, i.v.\n\nBortezomib: bortezomib given days -9, -6, and -2 at 1.0mg/m2, i.v.","id":"OG000","title":"Velcade for Anti-MM Therapy"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"180 days","title":"Therapeutic Efficacy","type":"PRIMARY","unitOfMeasure":"Participants"}